before, clinical trials on GLP-1 drugs have demonstrated their benefits as being a secondary prevention Device for cardiovascular disease (CVD), meaning they are able to lessen the probability of a heart attack or https://europeantimes.news/2024/08/belgium-battle-drugs-alcohol-hope/